Go Pro
→ Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown” (From Paradigm Press) (Ad)tc pixel Free STAB Stock Alerts

Statera Biopharma (STAB) Competitors

Statera Biopharma logo
$0.0002 0.00 (0.00%)
As of 09/2/2026
Compare

STAB vs. CMRA, EVLO, CALA, EFTR, and TRVN

Should you buy Statera Biopharma stock or one of its competitors? Statera Biopharma's main competitors and comparable companies include Comera Life Sciences (CMRA), Evelo Biosciences (EVLO), Calithera Biosciences (CALA), eFFECTOR Therapeutics (EFTR), and Trevena (TRVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Statera Biopharma compare to Comera Life Sciences?

Statera Biopharma (NASDAQ:STAB) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Comera Life Sciences N/A N/A N/A

Statera Biopharma has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Comera Life Sciences Neutral

Statera Biopharma has higher earnings, but lower revenue than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Summary

Comera Life Sciences beats Statera Biopharma on 3 of the 3 factors compared between the two stocks.

How does Statera Biopharma compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

0.3% of Evelo Biosciences shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by company insiders. Comparatively, 5.5% of Statera Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Evelo Biosciences had 1 more articles in the media than Statera Biopharma. MarketBeat recorded 1 mentions for Evelo Biosciences and 0 mentions for Statera Biopharma. Evelo Biosciences' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Statera Biopharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A
Statera BiopharmaN/AN/AN/AN/AN/A

Evelo Biosciences has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Statera Biopharma N/A N/A N/A

Summary

Evelo Biosciences beats Statera Biopharma on 4 of the 5 factors compared between the two stocks.

How does Statera Biopharma compare to Calithera Biosciences?

Calithera Biosciences (NASDAQ:CALA) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Calithera BiosciencesN/AN/A-$39.65MN/AN/A
Statera BiopharmaN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Calithera BiosciencesN/A N/A N/A
Statera Biopharma N/A N/A N/A

Calithera Biosciences has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market. Comparatively, Statera Biopharma has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market.

In the previous week, Calithera Biosciences' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
Calithera Biosciences Neutral
Statera Biopharma Neutral

Summary

Calithera Biosciences and Statera Biopharma tied by winning 1 of the 2 factors compared between the two stocks.

How does Statera Biopharma compare to eFFECTOR Therapeutics?

Statera Biopharma (NASDAQ:STAB) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Statera Biopharma has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.47, suggesting that its share price is 147% more volatile than the broader market.

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
eFFECTOR Therapeutics Neutral

Summary

eFFECTOR Therapeutics beats Statera Biopharma on 3 of the 4 factors compared between the two stocks.

How does Statera Biopharma compare to Trevena?

Trevena (NASDAQ:TRVN) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Statera Biopharma N/A N/A N/A

Statera Biopharma has lower revenue, but higher earnings than Trevena.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.00-$40.29M-$47.04N/A
Statera BiopharmaN/AN/AN/AN/AN/A

13.6% of Trevena shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 5.5% of Statera Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Trevena has a beta of -0.44, suggesting that its share price is 144% less volatile than the broader market. Comparatively, Statera Biopharma has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

In the previous week, Trevena's average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
Trevena Neutral
Statera Biopharma Neutral

Summary

Trevena and Statera Biopharma tied by winning 3 of the 6 factors compared between the two stocks.

Get Statera Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STAB vs. The Competition

Export
MetricStatera BiopharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3K$12.25B$7.26B$12.73B
Dividend YieldN/A2.59%2.53%8.86%
P/E Ratio0.00787.27273.2925.25
Price / SalesN/A754.88623.6797.64
Price / CashN/A94.8077.8252.26
Price / BookN/A12.3312.926.14
Net IncomeN/A$2.82B$3.47B$349.01M
7 Day PerformanceN/A2.60%0.60%-0.27%
1 Month PerformanceN/A6.96%5.72%0.68%
1 Year PerformanceN/A9.45%25.33%14.84%

Statera Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STAB
Statera Biopharma
N/A$0.00
flat		N/AN/A$3KN/AN/A20
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
EVLO
Evelo Biosciences
N/AN/AN/AN/A$2KN/AN/A120
CALA
Calithera Biosciences
N/A$0.00
flat		N/A+200.0%$1KN/AN/A60
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/A+300.0%$1KN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:STAB) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...
Eagle Publishing | Sponsoredtc pixel